February 2025 - Page 19 of 34

2024 CCHIO & CACA 40th Anniversary: A Landmark Event in Cancer Prevention and Treatment

By Lisa Cui 2025.02.17

On November 14, 2024, the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO) and the 40th Anniversary of the China Anti-Cancer Association (CACA) commenced at the Xi’an International Conference Center. Themed “CACA at 40: Carrying Forward and Innovating,” the event brought together medical experts, patient advocates, and leaders from various sectors to advance the fight against cancer.

Exploring Icosabutate for MASH: Insights from a Phase IIb Trial

By Mourabit Halima 2025.02.17

A recent phase IIb randomized trial, published in the Journal of Hepatology, evaluated Icosabutate, an oral FFAR1/FFAR4 agonist, in patients with biopsy-confirmed MASH and fibrosis (F1-F3). While the primary endpoint…

Advancing HCC Treatment: The Potential of Salsalate with Lenvatinib

By Mourabit Halima 2025.02.17

New research in JHEP Reports explores how Salsalate, a rheumatoid arthritis therapy, may enhance the effectiveness of Lenvatinib in treating MASH-driven hepatocellular carcinoma (HCC). By stimulating AMPK, enhancing fatty acid…

Immune Dysfunction and Infection Risk in Advanced Liver Disease

By Mourabit Halima 2025.02.17

The latest review in Gastroenterology explores the complex relationship between immune dysfunction and infection risk in advanced liver disease, highlighting the contributions of Brett McGettigan, Maria Hernandez-Tejero, Harmeet Malhi, and…

What Is the Optimal Locoregional Approach for Recurrent Hepatocellular Carcinoma?

By Mourabit Halima 2025.02.17

The Journal of Clinical Oncology features an important discussion led by Neil Newman MD MS, Colin Court, MD, PhD, and Alexander Parikh, MD, MPH on the best locoregional treatment strategies…

Addressing Alcohol Use Disorder Through a Gastroenterology & Hepatology Lens

By Lisa Cui 2025.02.17

Alcohol use disorder remains a leading but preventable cause of morbidity and mortality worldwide, with profound implications for chronic liver disease. Yet, despite its significant burden, clinicians often face challenges…

Advancing Liver Cancer Care: Join the EASL Liver Cancer Summit 2025 in Paris

By Mourabit Halima 2025.02.17

The EASL Liver Cancer Summit 2025 will take place in Paris from February 20-22, bringing together leading experts to discuss the latest developments in liver cancer diagnosis, prognosis, and treatment.…

Final Results from the NATALEE Trial: Ribociclib in Early Breast Cancer

By Mourabit Halima 2025.02.15

New data from the NATALEE trial reinforce the efficacy of ribociclib in combination with endocrine therapy for HR-positive, HER2-negative early breast cancer. With a median follow-up of 33.3 months, the…

Latest Insights in HER2+ Early Breast Cancer: KATHERINE Trial Final Analysis

By Mourabit Halima 2025.02.15

New findings from the KATHERINE trial, published in The New England Journal of Medicine, confirm that trastuzumab emtansine (T-DM1) continues to provide superior survival benefits over trastuzumab alone in HER2-positive…

Dr. Nan Bi Discusses Advances in Radiotherapy for NSCLC in 2024 | 2024 Precision Medicine Conference on Lung Cancer

By Yin, Jiale 2025.02.14

At the recently held 2024 Precision Medicine Conference on Lung Cancer, Dr. Nan Bi from the Cancer Hospital Chinese Academy of Medical Sciences, delivered a presentation titled "Advances in Radiotherapy for NSCLC in 2024." The talk covered key developments in radiotherapy combined with targeted therapy, radiotherapy combined with immunotherapy, and technological advancements in radiotherapy. In an exclusive interview with Oncology Frontier, Professor Bi further elaborated on some of the most pressing topics in this evolving field.